NBI-1065846

· Neurocrine Biosciences

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NBI-1065846, covering 2024-07-31 to 2024-07-31. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD [Phase 2]

See pricing